ArticleInfection2015
Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
Article in Infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance.BMC infectious diseases · 2019Guideline
- Personalized Approaches to Patients with Intra-Abdominal Infections.Journal of clinical medicine · 2025Review
- A nomogram for predicting the risk of tigecycline-associated drug-induced liver injury in a Chinese population.Scientific reports · 2025Article
- Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery.World journal of emergency surgery : WJES · 2024Review
- Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone.BMC cancer · 2023Article
- A Proposal for a Classification Guiding the Selection of Appropriate Antibiotic Therapy for Intra-Abdominal Infections.Antibiotics (Basel, Switzerland) · 2022Review
- Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- The effect of an antibiotic stewardship program on tigecycline use in a Tertiary Care Hospital, an intervention study.Annals of clinical microbiology and antimicrobials · 2020Article
- Tigecycline Therapy for Infections Caused by Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2020Article
- Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2020Article
- Carbapenem-Sparing Strategies for ESBL Producers: When and How.Antibiotics (Basel, Switzerland) · 2020Review
- Prevalence and Antimicrobial Resistance of Enterococci Isolated from Retail Meats in the United States, 2002 to 2014.Applied and environmental microbiology · 2018Article
- The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.World journal of emergency surgery : WJES · 2017Review
- Blue sky and some shadows: new antibiotics and new superbugs : The ECCMID 2016 in Amsterdam.Infection · 2016Article
- Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).World journal of emergency surgery : WJES · 2016Review
- Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006-2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST).GMS infectious diseases · 2016Article
- Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTigecycline is an established treatment option for infections with multiresistant bacteria (MRB). It retains activity against many strains with limited susceptibility to other antibiotics. Efficacy and safety of tigecycline as monotherapy or in combination regimens were investigated in a prospective noninterventional study involving 1,025 severely ill patients in clinical routine at 137 German hospitals. MATERIALS AND
methodsData on the full population have been published; our present analysis focuses on infections caused by MRB. The study population included patients with complicated infections, high disease severity (APACHE II > 15: 65 %) and high MRB prevalence. Most patients had comorbidities, including cardiovascular disease, renal insufficiency, and/or diabetes mellitus. Treatment success was defined as cure/improvement without requirement of further antibiotic therapy.
resultsPathogens isolated from 215 evaluable patients with documented MRB infections included 132 methicillin-resistant Staphylococcus aureus (MRSA), 42 vancomycin-resistant Enterococci (VRE) and 67 Gram-negative extended beta-lactamase (ESBL) producers. Of the MRB subpopulation, 140 patients received tigecycline monotherapy, 75 were treated with combination regimens. High overall clinical success rates were recorded for MRB infections treated with tigecycline alone (94 %) or in combinations (88 %); in detail intraabdominal infections (monotherapy: 90 %; combinations: 93 %), skin/soft tissue infections (93; 100 %), community-acquired pneumonia (100; 100 %), hospital-acquired pneumonia (94,7; 72,7 %), diabetic foot infections (89; 33 %), blood stream infections (100; 100 %) and multiple-site infections (92; 71 %).
conclusionsTigecycline achieved high clinical success rates in patients with documented infections involving MRB strains despite high disease severity. These results add to the evidence indicating that tigecycline is a valuable therapeutic option for complicated infections in severely ill patients with a high likelihood of multidrug-resistant pathogen involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.